CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $14.38M, lower than 95% of all stocks globally
- PositionGross margin is -15.3%, lower than 95% of its Biotechnology peers (median 67.1%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.27TKRW896.44M · vs all stocks (USD)
Revenue (TTM)
20.31BKRW14.38M · vs all stocks (USD)
Profit Margin
-77.62%vs Biotechnology peers
Beta
0.5580xvs all stocks
52-Week Change
113.00%vs all stocks
Market Capitalization
1.27TKRW896.44M · vs all stocks (USD)
Enterprise Value
1.38TKRW975.22M · vs all stocks (USD)
Price to Sales (TTM)
68.80xvs Biotechnology peers
Price to Book (MRQ)
13.78xvs Biotechnology peers
Enterprise to Revenue
67.83xvs Biotechnology peers
Enterprise to EBITDA
-111.92xvs Biotechnology peers
Gross Margin
-15.33%vs Biotechnology peers
Profit Margin
-77.62%vs Biotechnology peers
Operating Margin
-199.87%vs Biotechnology peers
Return on Assets (TTM)
-9.42%vs Biotechnology peers
Return on Equity (TTM)
-26.29%vs Biotechnology peers
Revenue (TTM)
20.31BKRW14.38M · vs all stocks (USD)
Revenue per Share (TTM)
675.73KRWUpdated Aug 19, 2026Quarterly Revenue Growth
69.40%vs Biotechnology peers
Gross Profit (TTM)
4.29BKRW3.04M · vs all stocks (USD)
EBITDA (TTM)
-12.31BKRW-8.71M · vs all stocks (USD)
Net Income (TTM)
-15.76BKRW-11.16M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
69.40%vs Biotechnology peers
Operating Cash Flow (TTM)
-11.65BKRW-8.25M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-42.82BKRW-30.32M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
19.32BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
15.67BKRWFY2025 · Dec 31, 2025Gross Profit
3.65BKRWFY2025 · Dec 31, 2025Operating Income
-12.19BKRW-8.63M · vs all stocks (USD)
Pre-tax Income
-16.45BKRWFY2025 · Dec 31, 2025Net Income
-16.45BKRWFY2025 · Dec 31, 2025EBIT
-14.31BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-8.74BKRWFY2025 · Dec 31, 2025Research & Development
28.38MKRWFY2025 · Dec 31, 2025Selling, General & Administrative
5.54BKRWFY2025 · Dec 31, 2025Other Operating Expenses
-194.20MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
449.95MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
2.14BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-16.45BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-15.90BKRWFY2025 · Dec 31, 2025Free Cash Flow
-58.52BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
40.43BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-16.45BKRWFY2025 · Dec 31, 2025Stock-based Compensation
1.46BKRWFY2025 · Dec 31, 2025Other Non-cash Items
1.44BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
177.55MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.53BKRWFY2025 · Dec 31, 2025Capital Expenditures
-42.62BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-34.26MKRWFY2025 · Dec 31, 2025Sale of Investments
9.46BKRWFY2025 · Dec 31, 2025Other Investing Activity
-187.66MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-33.35BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
39.43BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-11.69BKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-2.38BKRWFY2025 · Dec 31, 2025Other Financing Charges
12.06MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
67.37BKRWFY2025 · Dec 31, 2025Shares Outstanding
34.50MSharesUpdated Aug 19, 2026Float Shares
22.86MSharesUpdated Aug 19, 2026% Held by Insiders
29.53%vs all stocks
% Held by Institutions
0.67%vs all stocks
Total Cash (MRQ)
59.05BKRW41.81M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.76KKRWUpdated Aug 19, 2026Total Debt (MRQ)
43.67BKRW30.92M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4887xvs Biotechnology peers
Current Ratio (MRQ)
1.72xvs Biotechnology peers
Book Value per Share (MRQ)
2.66KKRWUpdated Aug 19, 2026Total Assets
123.04BKRW87.11M · vs all stocks (USD)
Total Current Assets
54.99BKRWFY2025 · Dec 31, 2025Total Liabilities
54.44BKRWFY2025 · Dec 31, 2025Total Non-current Assets
68.04BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
6.37BKRWFY2025 · Dec 31, 2025Total Current Liabilities
48.08BKRWFY2025 · Dec 31, 2025Cash
287.00KKRWFY2025 · Dec 31, 2025Cash Equivalents
40.43BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
40.43BKRWFY2025 · Dec 31, 2025Accounts Receivable
2.47BKRWFY2025 · Dec 31, 2025Inventory
4.85BKRWFY2025 · Dec 31, 2025Accounts Payable
1.57BKRWFY2025 · Dec 31, 2025Short-term Debt
38.04BKRWFY2025 · Dec 31, 2025Other Current Liabilities
1.00KKRWFY2025 · Dec 31, 2025Long-term Debt
5.27BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
120.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
15.98BKRWFY2025 · Dec 31, 2025Retained Earnings
-102.57BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
68.59BKRW48.57M · vs all stocks (USD)
52-Week Low
13.86KKRWUpdated Aug 19, 202652-Week High
49.90KKRWUpdated Aug 19, 202652-Week Change
113.00%vs all stocks
Beta
0.5580xvs all stocks
50-Day MA
35.37KKRWUpdated Aug 19, 2026200-Day MA
31.20KKRWUpdated Aug 19, 2026Avg 10-Day Volume
184.47KSharesUpdated Aug 19, 2026Avg 30-Day Volume
146.09KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-601.00KRWUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is -15.3%, lower than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: -0.15Industry median: 0.67Industry P5: 0.14Peers compared: 261
Financial Health
Altman Z-Score 12.63: safe zoneNotable
Altman Z-Score: 12.63
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $14.38M, lower than 95% of all stocks globallySignificant
Revenue (USD): 14,378,219.984Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
LB Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cloudbreak Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Biocause Heilen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Wit Dyne Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Isotope & Radiation Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
InMode Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Biotest Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wuhan Keqian Biology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hpgc Renmintongtai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wanbangde Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule